What's hot
View all perspectives
Jiha Lee JihaRheum
3 months ago
Deucravacitinib, the first oral TYK2 inhibitor, delivers in PsA:
✅ ACR20: 54% vs 34% (placebo)
✅ Skin, joints, fatigue, QoL
📉 Post hoc: less radiographic progression
No new safety signals at W16.
LB0001 @RheumNow #EULAR2025
Mrinalini Dey DrMiniDey
3 months ago
📊 In POETYK PsA-1, deucravacitinib (TYK2i) significantly improved ACR20 at W16 (54% vs 34% placebo) in bDMARD-naive PsA.
Also improved QoL, skin, and MSK outcomes.
Post hoc: slowed radiographic progression.
Well tolerated & no new safety signals
@RheumNow #EULAR2025 #LB0001
Mrinalini Dey DrMiniDey
3 months ago
📱 Axia, a digital therapeutic for #axSpa, led to significant improvements in BASDAI, BASFI & ASQoL in a 12-week RCT.
ASAS20: 51% vs 9%; ASAS40: 23% vs 3%.
Promising app-based intervention comprising individualised exercise, pt education & disease Mx.
@RheumNow #EULAR2025 #LB0002
Aurelie Najm AurelieRheumo
3 months ago
from Rituximab to BiTES to CAR T, always looking for deeper B cell depletion
Safety data from CC312 CD19/CD3/CD28, a triple engager in refractory moderate-to-severe SLE
So far so good but how far do we need to go?
#EULAR2025 @RheumNow LB0007
Jiha Lee JihaRheum
3 months ago
Older adults with chronic MSK pain report lower physical health—but better mental health—than younger peers.
Fewer missed work days, too.
Is this resilience, adaptation, or shifting expectations with age?
POS0402 @RheumNow #EULAR2025
Md Yuzaiful Md Yusof Yuz6Yusof
3 months ago
#EULAR2025 Abstr#LB0001 Phase 3 RCT of Deucravacitinib in psoriatic arthritis met endpoints (ACR20) over PBO at Week 16. Prespecified early radiographic was not significant but post-hoc (without imputed data) showed radiographic inhibition @RheumNow https://t.co/ORUBtUWH31
Janet Pope Janetbirdope
3 months ago
#EULAR2025 @eular_org update
#Recommendations #Rheumatoid #Rx
prof Smolen
subtle diff between former guidelines
MTX+GC
👇
D/C GCs rapidly
👇
If inadequate response
👇
Other csDMARDs are OUT ❎
✅go to bDMARD or tsDMARD*
TsDMARD after safety assessed
@RheumNow RecommendatnII https://t.co/yUrLdk6Eg1
Jiha Lee JihaRheum
3 months ago
Presenteeism and absenteeism in RA aren’t just about joints. In this UK study, comorbid anxiety, depression, and OA drove lost productivity.
Treating RA is not enough —holistic management matters.
POS0403 @RheumNow #EULAR2025
Mrinalini Dey DrMiniDey
3 months ago
🫁 In autoimmune ILD patients from FIBRONEER-ILD (n=325), nerandomilast slowed FVC decline vs placebo and reduced risk of ILD progression events (HR 0.56 for 18 mg BID).
Acceptable safety profile & tolerability.
@RheumNow #EULAR2025 #LB0003 https://t.co/aWsfNOL76n
Md Yuzaiful Md Yusof Yuz6Yusof
3 months ago
#EULAR2025 Abstr#LB0002 Crossover RCT of use of AXIA - a novel app-based intervention showed improvement in disease activity, functionality & quality of life in pople with Axial #SpA vs usual care. Available in Austria currently - awaiting rollout and in other languages @RheumNow https://t.co/nV4QifyikL
David Liew drdavidliew
3 months ago
Self-management of rheum disease is ripe for apps, gamification. How well does it work though?
This app (Axia) in axSpA was basically as good as a biologic.
Maybe you downplay non-pharm management, prob because we don’t do it well. This changes that
#EULAR2025 LB0002 @RheumNow https://t.co/sfhEJFsF89
Janet Pope Janetbirdope
3 months ago
#RA #recommendations #update
Some recommendations were merged
For sure some regions will consider
#Combination #csDMARDs or
Switch to another
👇🤔
#sulfasalazine
#leflunomide
Depends on access, pt preference, disease activity/severity
#EULAR2025 @RheumNow @eular_org https://t.co/QDPcHhvQiV
Mrinalini Dey DrMiniDey
3 months ago
🌳#WILLOW: TLR7/8 inhibition with enpatoran led to greater BICLA response, IFN signature reduction & skin improvement (CLASI-50/70) in active SLE vs placebo at 24wks. Most benefit seen in pts with high IFN-GS or GC use. Good tolerability.
@RheumNow #EULAR2025 #LB0004
Antoni Chan MD (Prof) synovialjoints
3 months ago
Presenting our abstract on remote monitoring in rheumatology at #EULAR2025 @RBNHSFT @UniofReading @HenleyBSchool @RheumNow https://t.co/palWjtX3gM
Jiha Lee JihaRheum
3 months ago
Tapering in RA?
In SORAIRO (n=149), pts in remission on ozoralizumab+MTX:
🧪 49% became MTX-free
⏱ 80% spaced OZR to q8w
CDAI ≤10 maintained in >90% if baseline remission + albumin >3.8
LB0006 @RheumNow #EULAR2025
Poster Hall